Cover Image
市場調查報告書

腎臟癌:開發平台分析

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 229726
出版日期 內容資訊 英文 1200 Pages
訂單完成後即時交付
價格
Back to Top
腎臟癌:開發平台分析 Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016
出版日期: 2016年06月08日 內容資訊: 英文 1200 Pages
簡介

腎臟癌,是腎臟細胞惡性化變成癌症,產生不能控制的腫瘤的疾病。症狀上有血尿、食慾不振、持續數週發燒、強烈疲勞感、貧血、呼吸急促、骨痛等。治療方法有外科手術、放射治療、化療等。

本報告提供腎臟癌的治療藥開發平台的現狀及最新更新的各開發階段比較分析、企業和研究機關正在開發的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 腎臟癌 概要

治療藥的開發

企業正在開發的治療藥

大學/機關研究中的治療藥

開發中產品概況

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

治療藥的評估

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8161IDB

Summary

Global Markets Direct's, 'Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016', provides an overview of the Kidney Cancer (Renal Cell Cancer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer)
  • The report reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Kidney Cancer (Renal Cell Cancer) therapeutics and enlists all their major and minor projects
  • The report assesses Kidney Cancer (Renal Cell Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Kidney Cancer (Renal Cell Cancer)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Kidney Cancer (Renal Cell Cancer) Overview
  • Therapeutics Development
  • Kidney Cancer (Renal Cell Cancer) - Therapeutics under Development by Companies
  • Kidney Cancer (Renal Cell Cancer) - Therapeutics under Investigation by Universities/Institutes
  • Kidney Cancer (Renal Cell Cancer) - Pipeline Products Glance
  • Kidney Cancer (Renal Cell Cancer) - Products under Development by Companies
  • Kidney Cancer (Renal Cell Cancer) - Products under Investigation by Universities/Institutes
  • Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics Development
  • Kidney Cancer (Renal Cell Cancer) - Therapeutics Assessment
  • Drug Profiles
  • Kidney Cancer (Renal Cell Cancer) - Recent Pipeline Updates
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects
  • Kidney Cancer (Renal Cell Cancer) - Discontinued Products
  • Kidney Cancer (Renal Cell Cancer) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2016
  • Number of Products under Development for Kidney Cancer (Renal Cell Cancer) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by 4SC AG, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by AbbVie Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Acceleron Pharma, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Advanced Cancer Therapeutics, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Advaxis, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Advenchen Laboratories, LLC, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Alethia Biotherapeutics Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Altor BioScience Corporation, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Ambrx, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Amgen Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Apcure SAS, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by APEIRON Biologics AG, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by arGEN-X BV, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Argos Therapeutics, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by ArQule, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Arrowhead Pharmaceuticals, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Astellas Pharma Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by AstraZeneca Plc, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by ATLAB Pharma SAS, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Aurigene Discovery Technologies Limited, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Bayer AG, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Berg LLC, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by BIND Therapeutics, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Bio-Cancer Treatment International Limited, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by BIOCAD, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Bionomics Limited, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Bionovis SA, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Boston Biomedical, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Caladrius Biosciences, Inc. , H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Calithera Biosciences, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by CASI Pharmaceuticals Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Celgene Corporation, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Cellceutix Corporation, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Celltrion, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Cellular Biomedicine Group, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Cerulean Pharma, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Chipscreen Biosciences Ltd, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Clonz Biotech Private Limited, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Coare Biotechnology, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Corcept Therapeutics Incorporated, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Corvus Pharmaceuticals, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Cytune Pharma SAS, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Ecrins Therapeutics SAS, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by EirGenix Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Eisai Co., Ltd., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Eli Lilly and Company, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Esperance Pharmaceuticals, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Exelixis, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Gene Techno Science Co., Ltd., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Genor BioPharma Co., Ltd., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by GenSpera, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Glycotope GmbH, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by HEC Pharm Co., Ltd., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Horizon Pharma Plc, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Hutchison MediPharma Limited, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Immatics Biotechnologies GmbH, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Immune Design Corp., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Immunicum AB, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by ImmunoFrontier, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by ImmunoGen, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Immunomedics, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Incuron, LLC, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Incyte Corporation, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Innate Immunotherapeutics Ltd, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Johnson & Johnson, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by KAHR medical Ltd., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by KineMed, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Komipharm International Co., Ltd., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Lead Discovery Center GmbH, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Mabion SA, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by MacroGenics, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by MaxiVAX SA, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by MediaPharma s.r.l., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by MedImmune, LLC, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Medivation, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Merck & Co., Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Merck KGaA, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Mirati Therapeutics Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Mirna Therapeutics, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Molecular Partners AG, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Mologen AG, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Monopar Therapeutics LLC, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Mycenax Biotech Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by NanoSmart Pharmaceuticals, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Nektar Therapeutics, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by NewLink Genetics Corporation, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Novartis AG, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by NovaTarg Therapeutics, Inc, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Omeros Corporation, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by OncBioMune Pharmaceuticals Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncobiologics, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncolys BioPharma Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by OncoMax, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Panacea Biotec Limited, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Peloton Therapeutics, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Pfizer Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Pharmicell Co., Ltd., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Pivotal BioSciences, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Plexxikon Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Prima BioMed Ltd., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by PsiOxus Therapeutics Limited, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Qu Biologics Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Recombio S.L, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Sanofi, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Seattle Genetics, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Selvita S.A., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Sevion Therapeutics, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Sillajen Biotherapeutics, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Sorrento Therapeutics, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Synthon Holdings BV, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Taiwan Liposome Company, Ltd., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Taris Biomedical LLC, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by TC BioPharm Limited, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Theravectys SA, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Tocagen Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by TVAX Biomedical, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Tyrogenex, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by United BioPharma, Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by UroGen Pharmaceuticals, Ltd., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Vascular Biogenics Ltd., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Vault Pharma Inc., H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Vaxeal Holding SA, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by ViiV Healthcare Limited, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by Vyriad, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Pipeline by X4 Pharmaceuticals, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Kidney Cancer (Renal Cell Cancer) Therapeutics - Recent Pipeline Updates, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..1), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..2), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..3), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..4), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..5), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..6), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..7), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..8), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..9), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..10), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..11), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..12), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..13), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..14), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..15), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..16), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..17), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..18), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..19), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..20), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..21), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Discontinued Products, H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..1), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..2), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..3), H1 2016
  • Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..4), H1 2016

List of Figures

  • Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2016
  • Number of Products under Development for Kidney Cancer (Renal Cell Cancer) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top